A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

The innovative program from the Family Heart Foundation includes being able to order a free test kit for an at-home blood ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

The industry also supports more than 70,000 jobs and is one of the most geographically and socially dispersed sectors of the ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best ...

A Missouri mother and her lawyers this week will aim to convince a jury that Abbott , Reckitt's Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she ...